The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multivariate analysis of factors affecting overall survival, event free survival, and 60-day mortality among AML patients treated with CPX-351 or intensive chemotherapy.
Eric Jay Feldman
Research Funding - Celator
Jeffrey E. Lancet
Research Funding - Celator
Jonathan E. Kolitz
Research Funding - Celator
Donna Hogge
Research Funding - Celator
Martin S. Tallman
Research Funding - Celator
Stuart L. Goldberg
Research Funding - Celator
Tibor Kovacsovics
Research Funding - Celator
Arthur Chin Louie
Employment or Leadership Position - Celator
Stock Ownership - Celator
Jorge E. Cortes
Research Funding - Celator